



Pharmaceutical applications – an advanced drug delivery system

- Pharmaceutical grade mesoporous magnesium carbonate (MMC) is denoted Pharma-MMC, is an optimized and defined variant of the regular MMC material
- Pharma-MMC is a proprietary, patent-protected drug delivery platform
- Pharma-MMC enables novel drug product formulations and improved versions of previously approved products
- Our current goal is to develop the innovative Pharma-MMC platform to meet current regulatory requirements and to clinically demonstrate the concept
- Poor water solubility of drugs is one of the major challenges facing the pharmaceutical industry. Amorphous drug delivery is therefore the “new big thing” within the pharmaceutical industry. Pharma-MMC addresses the challenge and meets the demand by offering unique opportunities of amorphous drug formulations
- The amorphous form of a drug substance has better solubility and dissolution rate than the corresponding crystalline form
- Pharma-MMC enables superior drug-load of up to 50% w/w.
- While the amorphous form of a drug typically lacks stability at storage, Pharma-MMC delivers long-term amorphous stability of loaded drugs (>12 months)
- The process properties meet stringent industry requirements
- The manufacturing process will meet current regulatory requirement (GMP)
- Timeline:
 - 2018: Evaluate potential products candidates, initiate drug development program, initiate scale-up program
 - 2019: Establish manufacturing of Pharma-MMC according to current Good Manufacturing Practice (cGMP), making Pharma-MMC ready for clinical trials
 - 2020-21: Enter clinical phase, establish drug product pipeline

For further information please contact:
Jenny Andersson Collby
Marketing Director

jenny.collby@disruptivematerials.com
Mobile +46 73 591 9818

Company information:
Disruptive Materials AB
Uppsala Science Park
Dag Hammarskjöldsväg 54B
SE-75183 Uppsala, Sweden
www.disruptivematerials.com

